Sorrento and Servier Partner to Further Develop Anti-PD-1 Antibody as Cancer Immunotherapy

Sorrento and Servier Partner to Further Develop Anti-PD-1 Antibody as Cancer Immunotherapy

Sorrento Therapeutics and Servier have entered into a license and collaboration agreement to develop, produce, and commercialize products using Sorrento’s fully human immuno-oncology anti-PD-1 monoclonal antibody (mAb) STI-A1110.

Sorrento’s proprietary immuno-oncology G-MAB library platform was used to identify and generate STI-A1110, which targets PD-1, an important immune checkpoint used in immunotherapeutic strategies.

The theoretical diversity of the library has been calculated to be more than one quadrillion unique antibodies, making it one of the largest fully human antibody collections available to pharmaceutical and biotechnology companies for drug discovery and development partnerships.

Under the terms of the agreement, Servier will have an exclusive worldwide license to Sorrento’s STI-A1110 mAb asset, covering all indications, including hematological and solid tumor cancers. Servier also gets full rights for the development, registration and commercialization of the products and will bear all costs for these actions.

Sorrento is to receive €25 million ($27.6 million) upfront, and is eligible for €151 million ($166.5 million) in development and regulatory milestones, €710 million ($782.8 million) in commercial milestones, and to royalties.

“We are excited about partnering on our anti-PD-1 immune checkpoint antibody with Servier, which is recognized for its scientific excellency and as a pioneer in CAR-T therapies. This agreement represents validation for Sorrento’s antibody technologies and R&D capabilities,” Dr. Henry Ji, president and CEO of Sorrento, said in a recent press release. “This also further establishes Sorrento as a notable immuno-oncology company with a comprehensive portfolio of clinical stage and preclinical immunotherapies. We look forward to working closely with the Servier team and growing this global partnership.”

“We have tested STI-A1110 in preclinical studies conducted at Servier and we believe that, used in combination with several products from our portfolio, it will lead to the development of new treatments for hematological as well as solid tumor cancers,” Dr. Jean-Pierre Abastado, director of the Oncology Innovation Therapeutic Pole for Servier, added.